Ligand Pharmaceuticals LGND Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.35M-130% | $44.78M-61.8% | $117.27M+2,319% | $4.85M+111% | -$42.45M-36.6% | ||
| $8.22M0.0% | $8.21M-0.7% | $8.27M-3.0% | $8.52M-2.8% | $8.77M+1.7% | ||
| $10.6M-25.7% | $14.27M-3.2% | $14.75M+47.5% | $10M+27.6% | $7.84M+4.1% | ||
| $13.53M+228% | -$10.57M+50.3% | -$21.28M-6,648% | $325K-96.3% | $8.84M-30.3% | ||
| $803K+42.1% | $565K+26.4% | $447K+258% | $125K-8.1% | $136K-20.9% | ||
| -$6.41M-407% | $2.09M-87.2% | $16.31M+490% | $2.77M+380% | $576K-89.8% | ||
| $4.14M+249% | -$2.77M+22.7% | -$3.59M-510% | $875K+75.0% | $500K+119% | ||
| $2.71M-63.0% | $7.35M+572% | $1.09M+369% | -$407K+81.1% | -$2.15M-119% | ||
| -$547K— | —— | $205K-75.0% | $821K-10.3% | $915K-80.1% | ||
| $0— | —— | —— | -$285K+2.7% | -$293K-115% | ||
| -$695K— | —— | -$864K+64.3% | -$2.42M-623% | -$335K+88.5% | ||
| -$732K-521% | $174K+123% | $78K+259% | -$49K-123% | -$22K-152% | ||
| $48.69M+6.0% | $45.92M+251% | $13.09M-17.1% | $15.8M+162% | -$25.45M-189% | ||
| $228K+2,433% | $9K-40.0% | $15K-93.0% | $214K0.0% | $214K-69.9% | ||
| $222.18M— | —— | $392.14M+519% | $63.34M+6.7% | $59.37M— | ||
| $1.3M-98.9% | $120.99M+65,297% | $185K— | $0-100% | $38.41M-3.5% | ||
| -$94.35M-421% | -$18.1M+94.9% | -$353.45M-3,213% | -$10.67M-318% | $4.89M+113% | ||
| $7.65M— | $0+100% | -$12.46M-251% | $8.24M+95.1% | $4.22M+35.8% | ||
| $7K0.0% | $7K+16.7% | $6K-14.3% | $7K0.0% | $7K+16.7% | ||
| $21.73M+6,217% | $344K+57.1% | $219K+51.0% | $145K-98.4% | $8.89M+359% | ||
| $50K-91.9% | $617K-95.8% | $14.84M+741,800% | $2K-97.2% | $71K-39.8% | ||
| -$14.13M-270% | $8.33M-98.0% | $409.65M+2,632% | $15M+416% | -$4.75M-123% | ||
| -$44K— | —— | —— | $2.29M+117% | $1.06M+168% | ||
| -$59.83M-268% | $35.55M-50.4% | $71.71M+264% | $19.68M+181% | -$24.32M-380% | ||
| $0— | —— | —— | -$2.74M-3,412% | -$78K— | ||
| $97K+341% | $22K-77.6% | $98K-5.8% | $104K+7.2% | $97K+9,600% | ||
| $774K-70.5% | $2.63M+323% | $621K-85.5% | $4.27M+1,426% | $280K-84.9% | ||
| $1.5M-25.5% | $2.02M+50.6% | $1.34M+74.7% | $766K-8.7% | $839K+38.4% | ||
| $803K+42.1% | $565K+26.4% | $447K+258% | $125K-8.1% | $136K-20.9% | ||
| $21K+111% | -$198K— | $0+100% | -$420K-27.3% | -$330K+61.3% | ||
| $479K-0.2% | $480K+0.2% | $479K+16.3% | $412K-27.8% | $571K0.0% | ||
| —— | $13.27M0.0% | $13.27M0.0% | $13.27M0.0% | $13.27M— | ||
| $3.87M-82.5% | $22.06M— | —— | —— | -$12.37M— | ||
| $13.53M+228% | -$10.57M+50.3% | -$21.28M-6,648% | $325K-96.3% | $8.84M-30.3% | ||
| -$695K— | —— | -$864K+64.3% | -$2.42M-623% | -$335K+88.5% | ||
| -$624K— | —— | —— | -$52K+97.2% | -$1.88M— | ||
| -$4.8M-165% | $7.37M+1,948% | $360K-15.7% | $427K-7.4% | $461K-40.9% | ||
| -$837K-172% | $1.16M+941% | $111K+256% | -$71K+59.2% | -$174K+96.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $5.11M+383% | $1.06M— | $0-100% | $7.62M— | ||
| $0-100% | $650K-92.3% | $8.39M— | $0-100% | $1.82M— | ||
| —— | $961.75K0.0% | $961.75K0.0% | $961.75K0.0% | $961.75K+53.9% | ||
| $222.18M+4.9% | $211.86M-46.0% | $392.14M+519% | $63.34M+6.7% | $59.37M-36.0% | ||
| $431K— | —— | —— | —— | $0-100% | ||
| $6.98M+367% | $1.5M-58.3% | $3.59M+76.7% | $2.03M-35.5% | $3.15M+24.1% | ||
| $119.35M+47.0% | $81.2M+52.4% | $53.29M+4.8% | $50.86M+57.2% | $32.36M+501% | ||
| $1.3M-98.9% | $120.99M+65,297% | $185K— | $0-100% | $38.41M-3.5% | ||
| $7K0.0% | $7K+16.7% | $6K-14.3% | $7K0.0% | $7K+16.7% | ||
| $50K-91.9% | $617K-95.8% | $14.84M+741,800% | $2K-97.2% | $71K-39.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$59.83M— | —— | $71.71M— | —— | -$24.24M— | ||
| $0— | —— | —— | -$2.74M-3,412% | -$78K— | ||
| $0— | —— | —— | $1.49M+79.6% | $828K— | ||
| -$732K-521% | $174K+123% | $78K+259% | -$49K-123% | -$22K-152% | ||
| $48.46M+5.6% | $45.91M+251% | $13.08M-16.1% | $15.59M+161% | -$25.66M-192% | ||
| $48.46M+5.6% | $45.91M+251% | $13.08M-16.1% | $15.59M+161% | -$25.66M-192% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.